Publications by authors named "A Hockaday"
Article Synopsis
- The study evaluates the effectiveness of a treatment regimen (ixazomib, thalidomide, and dexamethasone) followed by maintenance with ixazomib after salvage autologous hematopoietic stem-cell transplantation (HSCT) for patients with relapsed multiple myeloma, compared to observation.
- Conducted as part of a larger trial (Myeloma XII) across 79 UK hospitals, it involved patients aged 18+ with measurable disease and certain health criteria, randomized into two treatment groups.
- The primary measurement for effectiveness was progression-free survival, with safety assessments also being conducted, and a total of 206 patients participated in this phase of the trial.
Thoughtfully managed hydroperiods in natural and artificial wetlands could potentially provide a combination of desirable flood control services and high ecological functions. To explore how managed freshwater wetlands typical of the Houston, Texas area would respond to different hydrological regimes that might occur if wetlands were drained in anticipation of a heavy rain that did not materialize, we conducted a mesocosm experiment with six flooding depths and seven drought durations, followed by seven months of recovery. We found that the speed in which mesocosms dried out was a function of initial water depth, with mesocosms initially set with greater water depths (30 cm) taking ~ 38 days to dry out versus zero days for wetlands that were completely drained.
View Article and Find Full Text PDFArticle Synopsis
- * Involved 523 patients in a randomized trial, results showed significantly less disease progression and death in the ibrutinib-venetoclax group compared to the FCR group over a median follow-up of 43.7 months.
- * A large percentage of patients on the ibrutinib-venetoclax therapy achieved undetectable levels of measurable residual disease (MRD), indicating better long-term outcomes, while infection rates were
Background: The approval of Bruton tyrosine kinase (BTK) inhibitors in patients with previously untreated chronic lymphocytic leukaemia (CLL) was based on trials which compared ibrutinib with alkylating agents in patients considered unfit for fludarabine, cyclophosphamide, and rituximab, the most effective chemoimmunotherapy in CLL. We aimed to assess whether ibrutinib and rituximab is superior to fludarabine, cyclophosphamide, and rituximab in terms of progression-free survival.
Methods: This study is an interim analysis of FLAIR, which is an open-label, randomised, controlled, phase 3 trial in patients with previously untreated CLL done at 101 UK National Health Service hospitals.